NVZMY (Novonesis (Novozymes) B) Cyclically Adjusted Book per Share: $ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMY Novonesis (Novozymes) B NVZMY
90 GF Score
Price $66.01
GF Value $64.77
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Cyclically Adjusted Book per Share?

Novonesis (Novozymes) B NVZMY +0.40% 90 Cyclically Adjusted Book per Share is $ as of Jun. 2026. GuruFocus rates NVZMY with a GF Score™ of 90/100 and a GF Value™ of $64.77 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novonesis (Novozymes) B's adjusted book value per share for the three months ended in Jun. 2026 was $30.917. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $ for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novonesis (Novozymes) B's average Cyclically Adjusted Book Growth Rate was 25.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novonesis (Novozymes) B was 15.00% per year. The lowest was 4.60% per year. And the median was 7.15% per year.

As of today (2026-09-22), Novonesis (Novozymes) B's current stock price is $66.01. Novonesis (Novozymes) B's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $. Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novonesis (Novozymes) B was 13.63. The lowest was 5.18. And the median was 9.17.


Novonesis (Novozymes) B  (OTCPK:NVZMY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novonesis (Novozymes) B was 13.63. The lowest was 5.18. And the median was 9.17.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novonesis (Novozymes) B Cyclically Adjusted Book per Share Related Terms


Novonesis (Novozymes) B Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Cyclically Adjusted Book per Share Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novonesis (Novozymes) B Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NVZMY vs LIN, SHW, ECL: Cyclically Adjusted Book per Share Comparison

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B Cyclically Adjusted PB Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's Cyclically Adjusted PB Ratio falls into.


NVZMY
90GF Score
Novonesis (Novozymes) B NVZMY
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novonesis (Novozymes) B's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=30.917/122.9500*122.9500
=30.917

Current CPI (Jun. 2026) = 122.9500.

Novonesis (Novozymes) B Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.766 100.200 8.302
201612 6.832 100.300 8.375
201703 6.347 101.200 7.711
201706 6.783 101.200 8.241
201709 7.112 101.800 8.590
201712 7.597 101.300 9.221
201803 7.081 101.700 8.561
201806 7.098 102.300 8.531
201809 7.261 102.400 8.718
201812 7.493 102.100 9.023
201903 7.028 102.900 8.397
201906 7.261 102.900 8.676
201909 7.128 102.900 8.517
201912 7.577 102.900 9.053
202003 6.943 103.300 8.264
202006 7.196 103.200 8.573
202009 7.557 103.500 8.977
202012 8.193 103.400 9.742
202103 7.568 104.300 8.921
202106 7.780 105.000 9.110
202109 8.085 105.800 9.396
202112 8.355 106.600 9.636
202203 7.829 109.900 8.759
202206 7.891 113.600 8.540
202209 8.311 116.400 8.779
202212 9.163 115.900 9.720
202303 8.679 117.300 9.097
202306 9.055 116.400 9.565
202309 9.467 117.400 9.915
202312 9.512 116.700 10.021
202403 29.121 118.400 30.240
202406 28.706 118.500 29.784
202409 29.871 118.900 30.888
202412 28.062 118.900 29.018
202503 29.413 120.200 30.086
202506 30.619 120.700 31.190
202509 30.646 121.600 30.986
202512 30.931 121.180 31.383
202603 30.502 121.670 30.823
202606 30.917 122.950 30.917

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $ mean?
Novonesis (Novozymes) B (NVZMY) has a Cyclically Adjusted Book per Share of $ as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Cyclically Adjusted Book per Share too high?
Novonesis (Novozymes) B's current Cyclically Adjusted Book per Share is $. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Cyclically Adjusted Book per Share compare to LIN and SHW?
Novonesis (Novozymes) B's Cyclically Adjusted Book per Share of $ can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Chemicals company?
A good Cyclically Adjusted Book per Share depends on the Chemicals industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Cyclically Adjusted Book per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMY) is currently considered Fairly Valued. The stock's GF Value™ is $64.77, compared to a current price of $66.01 — trading 1.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is $. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMY), the current Cyclically Adjusted Book per Share is $ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (NVZMY) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $66.01 is trading 1.9% above its estimated GF Value™ of $64.77. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMY:

  • Cyclically Adjusted Book per Share: $
  • GF Value™: $64.77 vs. price of $66.01 (1.9% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NVZMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score

Get the complete analysis for NVZMY

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.01
Price
$64.77
GF Value